Pusan National University Researchers Identify Therapeutic Targets to Overcome Radioresistance of Brain Cancer Cells
Retrieved on:
Thursday, January 19, 2023
Cell, Radiation, Organic acid, Cell death, B cell, WHO, Pharmacokinetics, DNA, DAG, FDA, Pusan National University, Professor, Triglyceride, DGKB, Drug development, Neoplasm, Protein, Cladribine, Central nervous system, Patient, RNA, DGAT1, Research, Clinical trial, Recurrence, Reactive oxygen species, GBM, Temozolomide, Pharmaceutical industry, Vaccine, Glioblastoma
BUSAN, South Korea, Jan. 19, 2023 /PRNewswire/ -- Glioblastoma (GBM) is a WHO grade IV brain tumor with dismal prognosis. Although post-surgical radiation chemotherapy combined with temozolomide is the standard line of treatment, GBM cells surviving radiotherapy contribute to tumor progression and recurrence even more aggressively. Researchers have now unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. Moreover, the team has discovered a clinical drug that sensitizes GBM cells to radiotherapy and could replace temozolomide.
Key Points:
- Researchers have now unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance.
- Thus, there is an urgent need to revise the standard treatment strategy and develop a new therapy to overcome the radioresistance of GBM cells.
- In their study published in Cell Reports Medicine, the researchers derived GBM stem cells from patients and established radioresistant cells for investigation.
- Taken together, this study demonstrates that DGKB and DGAT1 are potential therapeutic targets for overcoming GBM radioresistance.